Cite
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
MLA
Anh Nguyen-Duc, et al. “Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.” JNCI: Journal of the National Cancer Institute, vol. 113, Feb. 2021, pp. 1005–16. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0a4daa288554717cfaddfd374c4734f0&authtype=sso&custid=ns315887.
APA
Anh Nguyen-Duc, Marina Nechaeva, Peter Schmid, Sherene Loi, Hiroji Iwata, Carlos H. Barrios, Andreas Schneeweiss, Véronique Diéras, Luciana Molinero, Hope S. Rugo, Sylvia Adams, Leisha A. Emens, Amreen Husain, Stephen Y. Chui, & Eric P. Winer. (2021). Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. JNCI: Journal of the National Cancer Institute, 113, 1005–1016.
Chicago
Anh Nguyen-Duc, Marina Nechaeva, Peter Schmid, Sherene Loi, Hiroji Iwata, Carlos H. Barrios, Andreas Schneeweiss, et al. 2021. “Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.” JNCI: Journal of the National Cancer Institute 113 (February): 1005–16. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0a4daa288554717cfaddfd374c4734f0&authtype=sso&custid=ns315887.